Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Koller

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Molecular Therapy. Nucleic Acids|August 30, 2021
A non-viral and selection-free <i>COL7A1</i> HDR approach with improved safety profile for dystrophic epidermolysis bullosaThomas Kocher, Johannes Bischof, Simone Alexandra Haas, et al.
The Journal of Dermatology|January 24, 2025
Repurposing diacerein for the treatment of chronic wounds in recessive-dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase-9 expressionSonja Dorfer, Michael Ablinger, Monika Wimmer, et al.
Cancer Letters|July 1, 2018
Cancer-type organic anion transporting polypeptide 1B3 is a target for cancer suicide gene therapy using RNA trans-splicing technologyYuchen Sun, Josefina Piñón Hofbauer, Manami Harada, et al.
Frontiers in Medicine|September 12, 2022
<i>COL17A1</i> editing <i>via</i> homology-directed repair in junctional epidermolysis bullosaIgor Petković, Johannes Bischof, Thomas Kocher, et al.
International Journal of Molecular Sciences|April 3, 2021
Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis BullosaMichael Ablinger, Thomas Lettner, Nicole Friedl, et al.
The Journal of Investigative Dermatology|September 18, 2020
QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical StudyOlivier Bornert, Marieke Hogervorst, Pauline Nauroy, et al.
The British Journal of Dermatology|September 8, 2023
MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomasJulia Illmer, Roland Zauner, Josefina Piñón Hofbauer, et al.
International Journal of Molecular Sciences|January 11, 2022
Evaluating a Targeted Cancer Therapy Approach Mediated by RNA <i>trans</i>-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin CancerKatharina Woess, Yuchen Sun, Hanae Morio, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 1, 2022
Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosaJohannes Bischof, Oliver Patrick March, Bernadette Liemberger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2025
Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosaMarkus Hierl, Johannes Bischof, Bernadette Liemberger, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Molecular Therapy. Nucleic Acids|August 30, 2021
A non-viral and selection-free <i>COL7A1</i> HDR approach with improved safety profile for dystrophic epidermolysis bullosaThomas Kocher, Johannes Bischof, Simone Alexandra Haas, et al.
The Journal of Dermatology|January 24, 2025
Repurposing diacerein for the treatment of chronic wounds in recessive-dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase-9 expressionSonja Dorfer, Michael Ablinger, Monika Wimmer, et al.
Cancer Letters|July 1, 2018
Cancer-type organic anion transporting polypeptide 1B3 is a target for cancer suicide gene therapy using RNA trans-splicing technologyYuchen Sun, Josefina Piñón Hofbauer, Manami Harada, et al.
Frontiers in Medicine|September 12, 2022
<i>COL17A1</i> editing <i>via</i> homology-directed repair in junctional epidermolysis bullosaIgor Petković, Johannes Bischof, Thomas Kocher, et al.
International Journal of Molecular Sciences|April 3, 2021
Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis BullosaMichael Ablinger, Thomas Lettner, Nicole Friedl, et al.
The Journal of Investigative Dermatology|September 18, 2020
QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical StudyOlivier Bornert, Marieke Hogervorst, Pauline Nauroy, et al.
The British Journal of Dermatology|September 8, 2023
MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomasJulia Illmer, Roland Zauner, Josefina Piñón Hofbauer, et al.
International Journal of Molecular Sciences|January 11, 2022
Evaluating a Targeted Cancer Therapy Approach Mediated by RNA <i>trans</i>-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin CancerKatharina Woess, Yuchen Sun, Hanae Morio, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 1, 2022
Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosaJohannes Bischof, Oliver Patrick March, Bernadette Liemberger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2025
Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosaMarkus Hierl, Johannes Bischof, Bernadette Liemberger, et al.
Pageof 8